Literature DB >> 6141278

Opioid receptor selectivity of dynorphin gene products.

I F James, W Fischli, A Goldstein.   

Abstract

In the guinea-pig ileum myenteric plexus-longitudinal muscle preparation, products from the dynorphin gene fell into three groups according to their potency. Dynorphin A was the most potent; dynorphin-32, dynorphin B, dynorphin B-29 and alpha-neo-endorphin were about equipotent and 10 to 20 times less potent than dynorphin A; dynorphin A-(1-8) and beta-neo-endorphin were about 200 times less potent than dynorphin A. Dynorphin A (a kappa agonist) was about 10 times less sensitive to antagonism by naloxone (as measured by naloxone Ke) than was normorphine (a mu agonist). Ke values for dynorphin-32, dynorphin B and alpha-neo-endorphin were the same as for dynorphin A, indicating that these peptides are also highly selective kappa agonists. Dynorphin A-(1-8), dynorphin B-29 and beta-neo-endorphin had Ke values intermediate between dynorphin A and normorphine, suggesting that they interact at both kappa and mu receptors. Addition of peptidase inhibitors to the bathing medium increased the potencies of dynorphin B, dynorphin B-29, alpha-neo-endorphin, dynorphin A-(1-8) and beta-neo-endorphin, but not of dynorphin A, dynorphin-32 or normorphine. The inhibitors did not change the naloxone Ke for dynorphin A or normorphine, or for dynorphin B-29, dynorphin A-(1-8) and beta-neo-endorphin, suggesting that the intermediate values were not caused by degradation to products with different receptor selectivities from the parent compounds. Ke for dynorphin-32, dynorphin B and alpha-neo-endorphin changed from being the same as dynorphin A in the absence of inhibitors to intermediate between dynorphin A and normorphine in the presence of inhibitors.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6141278

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

Review 1.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

2.  Evidence that the agonist action of dynorphin A(1-8) in the guinea-pig myenteric-plexus may be mediated partly through conversion to [Leu5]enkephalin.

Authors:  D M Dixon; J R Traynor
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

3.  Opioid receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus.

Authors:  C Chavkin; A Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

Review 4.  Role of kappa-opioid receptors in stress and anxiety-related behavior.

Authors:  Ashlee Van't Veer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

5.  Activation of κ opioid receptors increases intrinsic excitability of dentate gyrus granule cells.

Authors:  Carmel M McDermott; Laura A Schrader
Journal:  J Physiol       Date:  2011-05-23       Impact factor: 5.182

6.  Alanine scan of the opioid peptide dynorphin B amide.

Authors:  Anand A Joshi; Thomas F Murray; Jane V Aldrich
Journal:  Biopolymers       Date:  2017-09       Impact factor: 2.505

7.  Further studies on possible dynorphin involvement in the ovulatory luteinizing hormone surge in the proestrous rat.

Authors:  Qiang Zhang; Jennifer M McCoy; Robert V Gallo
Journal:  Endocrine       Date:  2002-08       Impact factor: 3.633

8.  Effect of prodynorphin-derived opioid peptides on the ovulatory luteinizing hormone surge in the proestrous rat.

Authors:  Qiang Zhang; Robert V Gallo
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

Review 9.  Dynorphin--still an extraordinarily potent opioid peptide.

Authors:  Charles Chavkin
Journal:  Mol Pharmacol       Date:  2012-11-14       Impact factor: 4.436

10.  Morphine and other opiates from beef brain and adrenal.

Authors:  A Goldstein; R W Barrett; I F James; L I Lowney; C J Weitz; L L Knipmeyer; H Rapoport
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.